Rafarmaisatrustedproviderof technological solutions for multiple advanced fields: High PurityAluminium, Photo& Diazo-TypePaper, ColloidMaterials;PhotoEmulsions,Medical-gradePolymers,MuonRadiography.
Rafarma Pharmaceuticals is a diversified pharmaceutical company
Biotech R&D projects reflect on the core values of the company, but the line-up of products that makes our independent work on innovative projects possible is much broader. Rafarma is a trusted provider of technological solutions for multiple advanced fields: High Purity Aluminium, Photo& Diazo-Type Paper, Colloid Materials; Photo Emulsions, Medical-grade Polymers, Muon Radiography.
By combining the power of boron compounds and neutron beams, we aim to destroy cancer cells with precision, minimizing damage to surrounding healthy tissues. Our end goal is the ultimate victory in the age- long fight with cancer. By supplying world’s leading medical professionals, we can help modern oncology to visualize and treat a variety of diseases at the molecular level by means of Radiopharmaceuticals.
Medical Isotopes is the heart of modern nuclear medicine. We stand as a trusted supplier of medical-grade isotopes to ensure that healthcare providers have the tools they need for accurate diagnosis and effective treatment, enhancing patient care on a global scale. As for the Orphan Diseases, we believe that every patient deserves a chance at a healthier life, regardless of the rarity of their condition. Repurposing existing compounds in accordance with the FDA standards fuels this race against time.
By combining the power of boron compounds and neutron beams, we aim to destroy cancer cells with precision, minimizing damage to surrounding healthy tissues. Our end goal is the ultimate victory in the age- long fight with cancer. By supplying world’s leading medical professionals, we can help modern oncology to visualize and treat a variety of diseases at the molecular level by means of Radiopharmaceuticals.
Medical Isotopes is the heart of modern nuclear medicine. We stand as a trusted supplier of medical-grade isotopes to ensure that healthcare providers have the tools they need for accurate diagnosis and effective treatment, enhancing patient care on a global scale. As for the Orphan Diseases, we believe that every patient deserves a chance at a healthier life, regardless of the rarity of their condition. Repurposing existing compounds in accordance with the FDA standards fuels this race against time.
Business development on the basis of high-tech industries within the concept of Industry 4.0
Production of biotechnology drugs and substances
Innovative lithium and boron-neutron-capture therapy for cancer treatment
R&D in the most promising segments of the biotech market autoimmune diseases, cancer, nervous diseases
High-purity and innovative materials, including colloidal chemistry products for various markets
ABOUT RAFARMA PHARMACEUTICALS
Biotech R&D projects reflect on the core values of the company, but the line-up of products that makes our independent work on innovative projects possible is much broader. Rafarma is a trusted provider of technological solutions for multiple advanced fields: High Purity Aluminium, Photo& Diazo-Type Paper, Colloid Materials; Photo Emulsions, Medical-grade Polymers, Muon Radiography.
Show more
Show more
Business development on the basis of high-tech industries within the concept of Industry 4.0
Production of biotechnology drugs and substances
Innovative lithium and boron-neutron-capture therapy for cancer treatment
R&D in the most promising segments of the biotech market autoimmune diseases, cancer, nervous diseases
High-purity and innovative materials, including colloidal chemistry products for various markets
Key objectives
Medical polymers;
Pharmaceutical substances and antibodies;
Photographic paper, diazo paper, holographic film;
Plates for muon spectrography;
Emulsion and colloidal photo materials;
Rafarma Assets
Super pure materials on the basis of aluminum A5N and A6N (99,9999%) for microelectronics;
Micron wire based on A5N aluminum;
Packaging materials for pharmaceuticals
Nuclear Medicine
- Isotope production
- Isotope-Based Products
- Boron Neutron Capture Therapy (BNCT) asa ServiceProject
- Radiopharmaceuticals and Devices forNuclear Medicine
our Products
R&D in Biotech
- Isotope production
- Isotope-Based Products
- Boron Neutron Capture Therapy (BNCT) asa ServiceProject
- Radiopharmaceuticals and Devices forNuclear Medicine
Biotech Products
- Drugs for orphandiseases
- Active pharmaceutical substances
- Radiotherapy
Market Overview
The use of radioisotopes in nuclear medicine is expected to grow rapidly dueto therising incidenceof cancer, increased public knowledge of nuclear therapy, and simplified applications of the technology.
Marketsize- 2023..................$8.82 B
Marketsize- 2033..................$19.04 B
Yearlygrowth(2023-2033)...8% CAGR
Marketsize- 2023..................$8.82 B
Marketsize- 2033..................$19.04 B
Yearlygrowth(2023-2033)...8% CAGR
The production of medical isotopes
Current Results
Kazakhstan deal
Reached a deal with Kazakhstan to get access to a 6 MGW nuclear reactor
Reached a deal with Kazakhstan to get access to a 6 MGW nuclear reactor
Equipmentpurchase
The purchaseof $12million worthof equipment for the Hong Kong plant has been completed, and the design of the equipment permit is underway
The purchaseof $12million worthof equipment for the Hong Kong plant has been completed, and the design of the equipment permit is underway
Isotopes selection
The most perspective isotopes have been selected forproduction
The most perspective isotopes have been selected forproduction
Theproductionof isotopes and isotope- based products is the main focus of the company at the moment.
The deal with the Government of Kazakhstan will allowRafarma tooccupy aunique position in the global market due to the combination of logistics, productioncapacities and competencies.
The deal with the Government of Kazakhstan will allowRafarma tooccupy aunique position in the global market due to the combination of logistics, productioncapacities and competencies.
Risks of conventional radiotherapy
More than 50% of cancer patients receive radiotherapy as part of their treatment. Withhigh efficiency in mostcases, today thetechnology is far from being perfect.
Side Effects:
Side Effects:
- Damage to healthy cells inaddition to tumor cells (radiationburns, hemorrhages, vascular fragility);
- Radiation reactions during the decay of healthy cells;
- Theingressof decay products of healthy cells into the blood, cascade reactions,nausea, weakness,a significant decreasein the quality of life.
Boron neutron capture therapy(BNCT)
Radiotherapy limitations
Although effectivein most cases, conventionalradiotherapy is not as effective in the difficult forms of cancer:
- Metastases in the later stages of the development of the disease;
- Glioblastoma (GBM);
- Melanoma;
- Tumors of the head and neck;
- Osteosarcoma;
- Tumors of the mammary gland;
- Brain tumors;
- Pancreascancer.
BNCT benefits & efficiency
BNCT is the advanced method of radiotherapy based on the reactions of radiosensitive drugs with isotopes inside tumorcells and the neutron beam.
In comparison with conventional radiotherapy methods, BNCT is significantlyless toxic,more comfortable forthe patient, andmore effective:
In comparison with conventional radiotherapy methods, BNCT is significantlyless toxic,more comfortable forthe patient, andmore effective:
- Less damage to healthy tissue
- Less severe side effects
- Short treatment (requires only 1-2 sessions)
BNCT technology — explained
Targeteddelivery ofradiosensitive non-toxicdrugs basedon stableisotopes of boron(BNCT) andlithium withsubsequent irradiationwith anepithermal neutron flux significantly increases efficiency and eliminates risks:
- Boron- or lithium-containing solution is injected into the patient's body.
- Targeted drug delivery to the affected cells is performed.
- Uponreaching the desired concentration of boron in cancer cells, irradiation with a neutron beam.
- Neutrons react with boron nuclei, energy is released, destroying the tumor cell without affecting the surrounding healthy tissues.
BNCT trials & results
2+
Glioblastoma
years in life expectancy
5 studies on 269 patients. The best results with BNCT arean increase in life expectancy after treatment up to two years.
76%
Brain and Neck Tumors
up to
5 studies on 220 patients. Complete response in primary cancers: 76%, in relapses: 36%, partial response: 68%. Reducing the size of tumors, improving the quality of life.
75%
Melanoma
up to
2 studies on 8 patients. The presence of a response to BNCT - 75%of cases. Currently, a clinical trial (NCT02759536) is being conducted in China on 30 patients, cases ofcomplete recoveryare described.
BNCT Market analysis
Rafarma is the second publicly trading company in the world to have a working BNCT prototype and competencies to work in the field. In total, 6 companies have access to the technology:
Market size 2022 — $11,37 M.
Predicted market size by 2028 — $265,26 M.
Yearly growth — 69,04% CAGR
Market size 2022 — $11,37 M.
Predicted market size by 2028 — $265,26 M.
Yearly growth — 69,04% CAGR
BNCT market potential
The technology is focused on the treatment of the most complex forms of cancer, including the most aggressive ones:
Potential market coverage - more than 1,480,000 cases of these forms of cancer per year:
- Tumors of the brain, thyroid gland
- Tumors of the head, neck, testicles
- Melanoma.
Potential market coverage - more than 1,480,000 cases of these forms of cancer per year:
Current Results
BNCT system testing
Prototype isready, the necessary tests are completed
Prototype isready, the necessary tests are completed
Portable version
The development of the portable BNCT system is in progress
The development of the portable BNCT system is in progress
Lithium capture therapy
R&D in Lithium Capture Therapy as a more effective alternativeto boron
R&D in Lithium Capture Therapy as a more effective alternativeto boron
BNCT is a technology with a high entry threshold and minimal competition as aresult. At the sametime, the development of technology willensure anaverage annualmarket growth of more than 69%.
Rafarma is in a unique position in the market: we already have the plant, the expertise, the experience and the ability to commercialize the equipment.
Assembly of products at factories in Hong Kong and Israel, and the concept of entering the market will allow the companyto vigorously advance in it.
Rafarma is in a unique position in the market: we already have the plant, the expertise, the experience and the ability to commercialize the equipment.
Assembly of products at factories in Hong Kong and Israel, and the concept of entering the market will allow the companyto vigorously advance in it.
Promoter solutions
In additionto accessto theBNCT acceleratoritself, the company hasthe expertiseand capacityto createthe production of radiosensitive drugs to improve the effectiveness of radiotherapy based on stable boron isotopes. Inthe future, the linecan beexpanded.
The production of isotope-based products, combined with the production of a particle accelerator for their use in the treatment of the mostdifficult forms of cancer, will allow the company toestablish aunique positionin theradiotherapy market.
The production of isotope-based products, combined with the production of a particle accelerator for their use in the treatment of the mostdifficult forms of cancer, will allow the company toestablish aunique positionin theradiotherapy market.
01. Boron-10 based products
Allow toachieve theconcentration of isotopes in a cancer cell 3-5 times higher in comparison with healthycells.
Allow toachieve theconcentration of isotopes in a cancer cell 3-5 times higher in comparison with healthycells.
02. Lithium-6 based products
With a similar principle of action,the energy release oflithium inthe affectedcell is around 100% (84% in thecase ofboron isotopes).
With a similar principle of action,the energy release oflithium inthe affectedcell is around 100% (84% in thecase ofboron isotopes).
Listeria-based solutions
Listeria bacteria can play a role in the selective delivery of isotopes to cancer cells. These bacteria have the ability to penetrate metastases and tumors, while beingeliminated bythe immune systemin healthy cells.
In radiotherapy, Listeria can beutilized for precise deliveryof isotopes such as Phosphorus-32 and Rhenium-188 to metastatic sites. Studies have shown that the achieved concentration of isotopes in cancer cells can go up to 15 times higher compared to healthy tissues.
The resultis a significantly enhanced effectiveness of radiotherapy, both in early and advanced stages of cancer, with minimalor negligible side effectsand harm to healthy tissues.
In radiotherapy, Listeria can beutilized for precise deliveryof isotopes such as Phosphorus-32 and Rhenium-188 to metastatic sites. Studies have shown that the achieved concentration of isotopes in cancer cells can go up to 15 times higher compared to healthy tissues.
The resultis a significantly enhanced effectiveness of radiotherapy, both in early and advanced stages of cancer, with minimalor negligible side effectsand harm to healthy tissues.
Targeted delivery agents for radiotherapy efficiency improvement
RAFARMA has been conducting research for over 10 years on a targeted drug based on radioactive Listeria (L. monocytogenes and L. welshimeri) for enhancing the effectiveness of radiotherapy.
Wepossess expertise, manufacturing capabilities, and the ability to advance the methodology to effectively treat the most challenging cancers.
Wepossess expertise, manufacturing capabilities, and the ability to advance the methodology to effectively treat the most challenging cancers.
The research on the technology is limited. The pace of studying the impact of different strains of Listeria on the effectiveness of radiotherapy has declined since 2017.
Currently, the methodology:
Currently, the methodology:
- Is not commercialized
- Is not being applied
- Lacks progress towards testing the effectiveness in vivo
- Lacks a foundation for human trials approval
Rafarma’s Solution
Orphan drugs market size
Rare (or orphan) diseases are diseases with a prevalence of no more than 10 cases per 100,000 population.
North America currently dominates the market for rare diseases medications, andit isexpected tomaintain itsleadership position.
Market size 2022 - $128.42 B
MArket size 2030 - $ 335.84B
Growth Rate - 12.8% CAGR
North America currently dominates the market for rare diseases medications, andit isexpected tomaintain itsleadership position.
Market size 2022 - $128.42 B
MArket size 2030 - $ 335.84B
Growth Rate - 12.8% CAGR
Orphan drugs development
With the increasing number of diseases and the rise in the number of cases each year, several smaller players are entering the market, holding asignificant share.
Competitive landscape
Current Results
The agreement in South Korea
We’ve achieved theagreement on establishing a biotechnological drugs manufacturing facility in South Korea
We’ve achieved theagreement on establishing a biotechnological drugs manufacturing facility in South Korea
Search & acquisition
We’ve initiatedthe search for potential partners inthe global market, witha focus on metabolicdiseases treatment
We’ve initiatedthe search for potential partners inthe global market, witha focus on metabolicdiseases treatment
At themoment, Rafarmahas no plans toinvest resourcesin entering the highly competitive orphan drug market “from scratch”. Instead, we have initiated a search for companiesalreadyregisteredin the global market that are open to collaboration.
By acquiringa biotechcompany with a portfolioof developments in the orphan drug segment, combining our expertise andleveraging themanufacturing capabilities, Rafarma aims to establish a strong market position with reducedrisks.
By acquiringa biotechcompany with a portfolioof developments in the orphan drug segment, combining our expertise andleveraging themanufacturing capabilities, Rafarma aims to establish a strong market position with reducedrisks.
Current state and statistics
Stroke is ranked as the second leading cause of death worldwidewith an annual mortality rate of about 5.5 million.
According to the WorldHealth Organization,from 1990to 2019, the number of recorded stroke cases has increased by 70%. Fatalities from stroke have increased by 43%, prevalence has risen by 102%.
According to World Stroke Organization estimates, every year stroketakes away 143 million years of healthy life globally due to the consequent death and disability.
According to the WorldHealth Organization,from 1990to 2019, the number of recorded stroke cases has increased by 70%. Fatalities from stroke have increased by 43%, prevalence has risen by 102%.
According to World Stroke Organization estimates, every year stroketakes away 143 million years of healthy life globally due to the consequent death and disability.
Rapid multifamorial stroke and TIA test
- Whenthe stroke is properly and correctly diagnosed, medical personnel has an effective window of 4.5 hours to start thrombolytics therapy.
- CT and MRI are the most common methods for diagnosing a stroke. in 1 out of10 cases, both are still not sufficiently effective for an accurate diagnosis.
Limitations of current stroke diagnosticstechniques
- For self-diagnosis, the most widespread technique is the FAST (Face ArmSpeech) test.However, itseffectiveness islimited, and the symptoms of transient ischemic attack (TIA) are often mistaken for "fatigue."
- In 50% of cases, TIA can lead to a stroke within 2 days, and in an additional 20% of cases, the stroke is expected within 90 days.
- Whenthe stroke is properly and correctly diagnosed, medical personnel has an effective window of 4.5 hours to start thrombolytics therapy.
- CT and MRI are the most common methods for diagnosing a stroke. in 1 out of10 cases, both are still not sufficiently effective for an accurate diagnosis.
- For self-diagnosis, the most widespread technique is the FAST (Face ArmSpeech) test.However, itseffectiveness islimited, and the symptoms of transient ischemic attack (TIA) are often mistaken for "fatigue."
- In 50% of cases, TIA can lead to a stroke within 2 days, and in an additional 20% of cases, the stroke is expected within 90 days.
20%
Misdiagnosis probability w/reliance on the FAST technique
1 of 10
Misdiagnosis occurrence with MRI and CT scans
4 hours
The window for effective thrombolytics therapy
Competitive landscape
Currently, there are no rapid and effective multifactorial tests available for stroke/TIA (Transient Ischemic Attack) on theglobal market.
Existing analogsare limitedin theirdistribution, relyingsolely on one factor, andare confinedto a singlemarket (theUnited States).
Existing analogsare limitedin theirdistribution, relyingsolely on one factor, andare confinedto a singlemarket (theUnited States).
60+
Of effective markers are not patented, not commercialized
90-95%
Precision of TIA / stroke detection based on the multifactorial use of the unpatented markers
Main goals
Primary objective is the development of a fast, accurate, and user- friendly multifactorialtest withunique properties:
- Quick results — results within a few minutes;
- User-friendlyinterface — similar to glucometers and pregnancy tests;
- Multifactorial analysis — determining the result based on4-5 markers and their ratios, rather than just one;
- Guaranteed 90% + accuracy — with the appropriate selectionof proven effectivemarkers and their proper analysis.
Simplicity of use benchmarks:
- Portable glucometers;
- At-home pregnancy tests;
- SARS-CoV-2 tests;
- Portable tests for blood pressure assessment.
Rafarma has successfully navigated a challenging geopolitical period and is prepared for new opportunities. We believe that our level of expertise, investments, and unique positioning at the intersection of multiple emerging fields will enable us to establish a dominant market position and make a significant contribution to the advancement of biotechnological industry.
our 2024 GOALS
Starting early summer of 2022, the management team has been developing a strategy that will tackle current market changes, maintain the company's scale and ensure investment security.
BNCT
Entry into the global market with BNCTequipment and solutions for neutron capture therapy.
Entry into the global market with BNCTequipment and solutions for neutron capture therapy.
Company strategy 2024-2028
MANUFACTURING
Establishmentof atleast 2 fullyequipped facilities for the productionof nuclear medical isotopes.
Establishmentof atleast 2 fullyequipped facilities for the productionof nuclear medical isotopes.
RADIOTHERAPY
Registration, commercialization of radiotherapy promoters on theglobal market.
Registration, commercialization of radiotherapy promoters on theglobal market.
FACILITIES
Commencement ofthe production oftheranostic devices and products in Hong Kong.
Commencement ofthe production oftheranostic devices and products in Hong Kong.
THERANOSTICS
Regulatory approvals, entry into theglobal marketwith theranostic devicedrugs.
Regulatory approvals, entry into theglobal marketwith theranostic devicedrugs.
Moving projects and expertise to open markets
Instead of unsafe operations with Russia-based assets, we will transfer our expertise to a more stable markets. Production lines will be moved to Hong-Kong, Kazakhstan and South Korea
Instead of unsafe operations with Russia-based assets, we will transfer our expertise to a more stable markets. Production lines will be moved to Hong-Kong, Kazakhstan and South Korea
Halting the project in Uzbekistan
The project in Uzbekistan has been halted until there is certainty in the legislation. We continue looking for acquisitions on the global market to further expand our portfolio
The project in Uzbekistan has been halted until there is certainty in the legislation. We continue looking for acquisitions on the global market to further expand our portfolio
Audit completin
The compromise have been reached and the audit will be completed.
The compromise have been reached and the audit will be completed.
Additional investment
The company's management invests its own funds to implement new projects through an increase in the company's raised capital without increasing the number of voting shares
The company's management invests its own funds to implement new projects through an increase in the company's raised capital without increasing the number of voting shares
RAFA Rafarma Pharmaceutical ISIN (CUSIP)
Number 75062C100
ID 012-000631222
Number 75062C100
ID 012-000631222
OFFICE
203 South Main Street, Suite 3000 Sheridan, Wyoming, 82801, USA
+1 (307) 429-2029
https://www.noyarp.com
babenko_press@rafapharm.com
203 South Main Street, Suite 3000 Sheridan, Wyoming, 82801, USA
+1 (307) 429-2029
https://www.noyarp.com
babenko_press@rafapharm.com
© 2024. All rights reserved.
Privacy Policy
Terms of Use of Data
Terms of Use of Data